Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe

被引：151

作者：

Ljungman, P

Urbano-Ispizua, A

Cavazzana-Calvo, M

Demirer, T

Dini, G

Einsele, H

Gratwohl, A

Madrigal, A

Niederwieser, D

Passweg, J

Rocha, V

Saccardi, R

Schouten, H

Schmitz, N

Socie, G

Sureda, A

Apperley, J

机构：

[1] Karolinska Univ Hosp, Dept Hematol, S-14186 Huddinge, Sweden

[2] Hosp Clin Barcelona, Barcelona, Spain

[3] Hop Necker Enfants Malad, Dept Biotherapy, Paris, France

[4] Ankara Univ, Sch Med, Ibn I Sina Hosp, Dept Hematol Oncol, TR-06100 Ankara, Turkey

[5] IRCCS G Gaslini, Dept Paediat Haematol & Oncol, Genoa, Italy

[6] Univ Wurzburg, Dept Hematol & Oncol, Wurzburg, Germany

[7] Univ Basel Hosp, Div Hematol, CH-4031 Basel, Switzerland

[8] Royal Free Hosp, Anthony Nolan Bone Marrow Trust, London NW3 2QG, England

[9] Univ Leipzig, Dept Hematol & Oncol, D-7010 Leipzig, Germany

[10] Univ Hosp Geneva, Div Hematol, Geneva, Switzerland

[11] Hop St Louis, Dept Hematol, BMT Unit, Paris, France

[12] Careggi Hosp & Univ Florence, Dept Hematol, Florence, Italy

[13] State Univ Limburg Hosp, Dept Internal Med, Hematol Oncol Sect, NL-6201 BX Maastricht, Netherlands

[14] Allgemein Krankenhaus St Georg, Dept Hematol, Hamburg, Germany

[15] Hosp Santa Cruz & San Pablo, Clin Hematol Div, E-08025 Barcelona, Spain

[16] Hammersmith Hosp, Imperial Coll Sch Med, Dept Haematol, London, England

来源：

BONE MARROW TRANSPLANTATION | 2006年 / 37卷 / 05期

关键词：

haemopoietic stem cell transplantation; indications; practice; Europe;

D O I：

10.1038/sj.bmt.1705265

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

The Accreditation Subcommittee of the EBMT regularly publishes special reports on current practice of haemopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred since the first report was published in 1996. Haemopoietic stem cell transplantation today includes grafting with allogeneic and autologous stem cells derived from bone marrow, peripheral blood and cord blood. With reduced intensity conditioning regimens in allogeneic transplantation, the age limit has increased, permitting the inclusion of older patients. New indications have emerged such as autoimmune disorders and AL amyloidosis for autologous, and solid tumours for allogeneic transplants. The introduction of alternative therapies has challenged well-established indications such as imatinib for chronic myeloid leukaemia. An updated report with revised tables and operating definitions is presented here.

引用

页码：439 / 449

页数：11

共 7 条

[1] Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents:: The histocompatibility and alternate stem cell source working committee of the International Bone Marrow Transplant Registry [J].